Is lava Therapeutics owned by institutional investors?
Only 34.61% of the stock of Lava Therapeutics B.V. is held by institutions. Earnings for Lava Therapeutics B.V. are expected to grow in the coming year, from ($2.14) to ($2.13) per share. Is Lava Therapeutics B.V. a buy right now?
Does lava Therapeutics (LVA) have an upside of 293%?
According to analysts' consensus price target of $21.67, Lava Therapeutics B.V. has a forecasted upside of 293.9% from its current price of $5.50. Lava Therapeutics B.V. has only been the subject of 1 research reports in the past 90 days.
What is ledlava Therapeutics NV (LVA)?
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET).
Is Lava Therapeutics a good stock to buy?
LAVA Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Should I buy LVTX stock?
The consensus among 1 Wall Street analyst covering (NASDAQ: LVTX) stock is to Buy LVTX stock.
Is LVTX stock a buy right now?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last year. There are currently...
Will LAVA Therapeutics' stock price go up in 2022?
1 brokers have issued 12-month target prices for LAVA Therapeutics' shares. Their forecasts range from $25.00 to $25.00. On average, they expect LA...
How has LAVA Therapeutics' stock price performed in 2022?
LAVA Therapeutics' stock was trading at $5.50 on January 1st, 2022. Since then, LVTX shares have decreased by 49.6% and is now trading at $2.77. V...
Are investors shorting LAVA Therapeutics?
LAVA Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,400 shares, an increase...
When is LAVA Therapeutics' next earnings date?
LAVA Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for LAV...
How were LAVA Therapeutics' earnings last quarter?
LAVA Therapeutics (NASDAQ:LVTX) posted its earnings results on Tuesday, May, 17th. The company reported ($0.41) EPS for the quarter, beating analys...
Who are LAVA Therapeutics' key executives?
LAVA Therapeutics' management team includes the following people: Mr. Stephen Allen Hurly M.B.A. , M.Sc., CEO & Exec. Director (Age 54) Mr. Pete...
Who are some of LAVA Therapeutics' key competitors?
Some companies that are related to LAVA Therapeutics include Viemed Healthcare (VMD) , Icosavax (ICVX) , Talkspace (TALK) , Alpine Immune Scien...
When did LAVA Therapeutics IPO?
(LVTX) raised $100 million in an initial public offering on Thursday, March 25th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per sha...
What is LAVA Therapeutics' stock symbol?
LAVA Therapeutics trades on the NASDAQ under the ticker symbol "LAVA."
What is LAVA Therapeutics' official website?
The official website for LAVA Therapeutics is www.magma-da.com .
How can I contact LAVA Therapeutics?
LAVA Therapeutics' mailing address is 1650 Technology Drive, SAN JOSE, CA 95110, United States . The technology company can be reached via phone a...
About Lava Therapeutics B.V
3.5 Analyst's Opinion
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform.
Is Lava Therapeutics B.V. a buy right now?
Lava Therapeutics B.V. has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Are investors shorting Lava Therapeutics B.V.?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lava Therapeutics B.V. in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Lava Therapeutics B.V. stock. View analyst ratings for Lava Therapeutics B.V. or view top-rated stocks.
When is Lava Therapeutics B.V.'s next earnings date?
Lava Therapeutics B.V. saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 6,200 shares, a decrease of 55.1% from the December 31st total of 13,800 shares. Based on an average daily trading volume, of 23,300 shares, the short-interest ratio is currently 0.3 days.
How were Lava Therapeutics B.V.'s earnings last quarter?
Lava Therapeutics B.V. is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022. View our earnings forecast for Lava Therapeutics B.V..
What price target have analysts set for LVTX?
Lava Therapeutics B.V. (NASDAQ:LVTX) announced its quarterly earnings results on Sunday, November, 14th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.01. The company earned $2.10 million during the quarter. View Lava Therapeutics B.V.'s earnings history.
What is LAVA Therapeutics' stock symbol?
3 brokers have issued 1-year price objectives for Lava Therapeutics B.V.'s stock. Their forecasts range from $20.00 to $23.00. On average, they anticipate Lava Therapeutics B.V.'s stock price to reach $21.67 in the next twelve months.
Where are LAVA Therapeutics' headquarters?
LAVA Therapeutics trades on the NASDAQ under the ticker symbol "LAVA."
How can I contact LAVA Therapeutics?
LAVA Therapeutics is headquartered at 1650 Technology Drive, SAN JOSE, CA 95110, United States.
